Indegene empowered an innovative medical devices company to launch a product addressing Pelvic Organ Prolapse (POP), affecting ~57 million US women, by overcoming limited in-house expertise in clinical, regulatory, safety, medical affairs, and commercialization. Challenges included educating HCPs and raising patient awareness on unique benefits, scaling end-to-end launch operations, and finding a partner for co-commercialization with shared risk. Indegene's software delivered a flexible, digital-first model with high-touch engagement, streamlining processes from planning to post-launch vigilance for accelerated market entry and equitable value sharing.

Join for free to read